Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $22.50, for a total value of $22,500.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Benjamin Hohl also recently made the following trade(s):
- On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.
- On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.72, for a total transaction of $346,080.00.
- On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $59,312.50.
- On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.
Enliven Therapeutics Price Performance
Shares of Enliven Therapeutics stock opened at $24.70 on Wednesday. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00. The firm has a market capitalization of $1.16 billion, a P/E ratio of -11.28 and a beta of 1.05. The company's 50 day moving average price is $17.67 and its two-hundred day moving average price is $14.89.
Crypto Pioneer Says: “The last crypto bull market has begun.”
From InvestorPlace | Ad
Right now, there’s over $6 trillion in potential investment money waiting on the sidelines.
That means this crypto bull market has a lot more room to run before it comes close to being a bubble.
Click here if you’d like to learn more about these five cryptos…
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.09. On average, analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in ELVN. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics in the third quarter worth about $157,000. China Universal Asset Management Co. Ltd. purchased a new position in Enliven Therapeutics in the fourth quarter worth $66,000. Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. AJOVista LLC bought a new stake in Enliven Therapeutics during the fourth quarter worth about $28,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company's stock worth $121,000 after buying an additional 2,208 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a "buy" rating and a $34.00 price target on the stock.
Read Our Latest Stock Analysis on Enliven Therapeutics
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
